EPHA2 and prostate carcinoma: EPHA2 ligand-independent activation, characterized by phosphorylation at S897, has been reported to contribute to metastasis in many tumors, such as colon cancer (Dunne et al., 2016), glioma (Miao et al., 2015), prostate cancer (Tawadros et al., 2012), and NPC (Li J. Y. et al., 2019).